Revolution Medicines, Inc. (RVMD)
Develops cancer drugs that target and block faulty RAS proteins driving tumor growth.
$182.49-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+398.2%
The outlook
RVMD is trading near the top of its 52-week range and above both its 50- and 200-day moving averages, signaling upward momentum in the near term. Analysts overwhelmingly favor the stock with a "Strong Buy" consensus, and their average price target sits roughly 13% above the current price. The stock shows strong technical positioning alongside broad analyst support.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 21 analysts
Price trendAbove its 50- & 200-day averages
52-week range92% of the way from its 52-week low to high
Price targetAvg target +13% vs current price
Analyst price target
~12-month · 21 analysts$207.00average target+13.4% vs now
Now $182.49
Low $151.00High $263.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$38.80B
52-wk high
$194.56
52-wk low
$34.00
50-day avg
$168.45
200-day avg
$112.69
Trailing P/E
—